Mayo Clinic bone marrow cancer study uncovers potential new drug targets
Newly published research from Mayo Clinic's Center for Individualized Medicine shows that patients with ASXL1-mutant chronic myelomonocytic leukemia possess distinctive epigenetic alterations that can trigger harmful genes and accelerate the cancer’s growth. ASXL1-mutant chronic myelomonocytic leukemia is a rare form of bone marrow cancer that can also turn into more aggressive acute myeloid leukemia.
Published in Nature Communications, the study found that:
Moritz Binder, M.D., a Mayo Clinic hematologist who led the study, says the study and its results not only add to the knowledge of ASXL1 gene expression, but will also help guide potential new therapeutic strategies for patients.